Manufacturing & Packaging

The facility, company says, will be its first that covers end-to-end ADC production.

The CDMO’s latest business venture reaffirms its commitment to the development of novel radiopharmaceuticals.

The company has financially committed more than $3.8 billion since the COVID-19 pandemic into keeping the medication and vaccine production process in France.

The development project adds an additional 157,500 square feet to the existing facility in the process.

The CDMO’s Bedford, NH facility will welcome a new isolator filling line—along with twin lyophilizers—as part of a multi-year, $100 million capital investment project.

The CDMO’s boost in production will be centered around pharmaceutical products.

The company adds a top-10 CDMO to its portfolio in the process, while also expanding its commitment to the pharma industry.

The deal further grows the Big Pharma company’s US production capabilities, especially when it comes to global parenteral products.

The acquisition initiates a long-term agreement with Beacon Therapeutics, highlighted by clinical and commercial AAV production.

The purpose for the deal, the CDMO says, is to meet the demand for commercial mammalian contract manufacturing.

A proposed Senate bill is intended to protect citizens’ private health and genetic information.

The CDMO’s multi-million-dollar expansion project features commercial manufacturing suites and peptide manufacturing plants.

The purchase boosts the parties’ sterile liquid manufacturing capabilities.

The partnership revolves around meeting various agency standards and industry requirements pertaining to the drug development and manufacturing lifecycle.

The new seals include sustainable film material containing recyclate content of up to 90%.

Properly supporting market access for a newly launched product with a single indication is challenging. Doing so for multiple indications, or supporting subsequent indications, can have a compounding effect on the degree of difficulty for getting everything right.

RLG Healthcare will focus on specialty pharmaceuticals and healthcare packaging.

The pharma powerhouse is investing $300 million in a plant that could be vital for the future cancer trials.

The deal is expected to help boost supply of Wegovy.

An analysis of the two main new models for pharmacy—unique direct—to-consumer for brands and cash pay for generics—and what members of industry think about them.

Leading experts in the sector explore the value of third-party logistics providers when it comes to fortifying pharmaceutical supply chains.

Duplicate rebates have resulted in revenue leakage for manufacturers.

As a result, time to treatment for the brand Gilead product is expected to increase from 16 to 14 days.

The pharmaceutical packaging company unveils a new siliconization line at its SQLM plant in France.

The latest financial commitment adds 24,000 liters of biologics drug substance-capacity to the company’s network.

The Identification of Medicinal Product framework seeks to establish a common language for identifying, documenting, and exchanging information about medicinal products.

Acquisition is expected to strengthen company’s CDMO business, while establishing a footprint in the generics space.

Roots Analysis report suggests increase can be attributed to the growing demand for advanced therapies and biologics.

Manufacturers should leverage the knowledge base of personnel working in sterility assurance and in microbiology laboratories.

Review article explores the latest developments surrounding expression and purification strategies.